Alliance expands to include taxane purification
Novasep and instrAction have expanded their worldwide strategic alliance to include the purification of taxanes, a well-known class of anti-cancer compounds.
Novasep and instrAction have expanded their worldwide strategic alliance to include the purification of taxanes, a well-known class of anti-cancer compounds.
Novasep supplies manufacturing solutions to the life science industries, while instrAction manufactures stationary phases for API purification processes. The two companies announced a strategic alliance covering non-chiral chromatography in July 2010, and this extended collaboration will now allow Novasep to develop and operate or supply optimized large-scale chromatography processes for purification of taxane-based active pharmaceutical ingredients (APIs) and intermediates.
“Thanks to instrAction’s highly selective chromatographic stationary phases and Novasep’s 20 years’ experience in taxane synthesis and purification, we are looking to see a paradigm shift in solutions for our customers worldwide as a result of this collaboration,” says René De Vaumas, executive vice president in charge of Novasep Synthesis’ business development.
instrAction has synthesized a family of API-selective stationary phases among their 3000-phase library, which are reported to have shown a strong potential for the purification of various taxanes. Access to instrAction’s technology means Novasep expects to be able to develop a multi-step synthesis or semi-synthesis. The company can then scale up the optimized process and produce the API for clinical and commercial purposes. Alternatively, it can supply the developed process to its customers with performance guarantees, integrating its Prochrom HPLC columns and systems and instrAction’s selective stationary phases.
“We are delighted about our extended collaboration with Novasep,” said Dr Thomas Schwarz, CEO of instrAction. “The cooperation with Novasep in the field of taxane purification is a further important milestone to implement the instrAction technology in industrial downstream processes. We are very confident that it will be broadly applied to the industrial purification of APIs in the future.”
For more information on the companies visit www.novasep.com and www.instraction.com
An LC–HRMS Method for Separation and Identification of Hemoglobin Variant Subunits
March 6th 2025Researchers from Stanford University’s School of Medicine and Stanford Health Care report the development of a liquid chromatography high-resolution mass spectrometry (LC–HRMS) method for identifying hemoglobin (Hb) variants. The method can effectively separate several pairs of normal and variant Hb subunits with mass shifts of less than 1 Da and accurately identify them in intact-protein and top-down analyses.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
